key: cord-0968563-u73ss00a
authors: Joe, Carina C D; Segireddy, Rameswara R; Oliveira, Cathy; Berg, Adam; Li, Yuanyuan; Doultsinos, Dimitrios; Chopra, Nitin; Scholze, Steffi; Ahmad, Asma; Nestola, Piergiuseppe; Niemann, Julia; Douglas, Alexander D
title: Accelerating manufacturing to enable large-scale supply of a new adenovirus-vectored vaccine within 100 days
date: 2021-12-23
journal: bioRxiv
DOI: 10.1101/2021.12.22.473478
sha: 176c4d66e86e80dc98107c0646777b11007201cc
doc_id: 968563
cord_uid: u73ss00a

The Coalition for Epidemic Preparedness Innovations’ ‘100-day moonshot’ aspires to launch a new vaccine within 100 days of pathogen identification. Here, we describe work to optimize adenovirus vector manufacturing for rapid response, by minimizing time to clinical trial and first large-scale supply, and maximizing the output from the available manufacturing footprint. We describe a rapid viral seed expansion workflow that allows vaccine release to clinical trials within 60 days of antigen sequence identification, followed by vaccine release from globally distributed sites within a further 40 days. We also describe a new perfusion-based upstream production process, designed to maximize output while retaining simplicity and suitability for existing manufacturing facilities. This improves upstream volumetric productivity of ChAdOx1 nCoV-19 by around four-fold and remains compatible with the existing downstream process, yielding drug substance sufficient for 10000 doses from each liter of bioreactor capacity. Transition to a new production process across a large manufacturing network is a major task. In the short term, the rapid seed generation workflow could be used with the existing production process. We also use techno-economic modelling to show that, if linear scale-up were achieved, a single cleanroom containing two 2000 L bioreactors running our new perfusion-based process could supply bulk drug substance for around 120 million doses each month, costing <0.20 EUR/dose. We estimate that a manufacturing network with 32000 L of bioreactor capacity could release around 1 billion doses of a new vaccine within 130 days of genomic sequencing of a new pathogen, in a hypothetical ‘surge campaign’ with suitable prior preparation and resources, including adequate fill-and-finish capacity. This accelerated manufacturing process, along with other advantages such as thermal stability, supports the ongoing value of adenovirus-vectored vaccines as a rapidly adaptable and deployable platform for emergency response.

seeded with approximately 0.5 × 10 6 cells/mL in approximately 80% of the maximum working 184 volume, and infected 28-30 hours later at a MOI of 6 VP/cell and viable cell density of 185 approximately 0.8 × 10 6 cells/mL. Cell cultures were fed with BalanCD medium 5% v/v at 48 186 hours and 96 hours after infection (±4 hours). Temperature was reduced within 4 hours of 187 the second feed. Cultures were harvested approximately 140 hours after infection and virus 188 was partially purified as described above. 189

For high-throughput screening of process conditions, the multi-parallel bioreactor and 192 perfusion system Ambr®250 High Throughput Perfusion (Ambr250 HT Perfusion; Sartorius) 193 was used with 0.2 µm hollow-fibre filters in ATF mode. The total reactor volume was 210 mL 194 per vessel and the stirring power input was 40 W/m 3 . Temperature was controlled at 37°C, 195 dissolved oxygen (DO) was controlled at 55 % by sparging with air and/or O2, and pH was 196 controlled at 7.25 (dead-band, 0.05) by sparging with CO2 mix or addition of 1M sodium 197 bicarbonate. Antifoam C emulsion 30% (Sigma-Aldrich) was diluted to 2% and automatically 198 added as required via the Ambr250 integrated foam sensor and liquid handler. Each 199

Ambr250 vessel was filled with pre-warmed BalanCD HEK293 medium and seeded with 0.5 200 × 10 6 viable T-REx-293 cells/mL. After 3 days, cells were bled and replenished to reactor 201 working volume containing 1 x 10 6 viable cells/mL (thus modelling pre-production 'n-1' cell 202 seed culture expansion in a stirred tank reactor). Nutrient supplementation used 5% 203 BalanCD HEK293 feed, as described below. 204

Viable cell density was measured daily using a Cedex HiRes® Analyzer (Roche). 205

Metabolites were automatically analysed daily via the integrated BioProfile® FLEX2 device 206 (Nova Biomedical). Samples for adenoviral vector quantification by quantitative PCR (see 207 below) were taken 44 and 48 hours after infection. For each timepoint, VP counts were 208 calculated as the mean of triplicate samples, each analysed in triplicate wells on triplicate 209

plates. The mean of the 44-hour and 48-hour values was used for analysis. 210

Experimental design 211 factorial experiments each comprised two levels of these three factors (2 × 2 × 2), in eight 217 single bioreactors. Each experiment also included one 'centre-point' condition (in triplicate 218 bioreactors) and one 'simplified centre-point-like' condition (singly or in duplicate), for a total 219 of 12 parallel bioreactors in the first experiment and 13 in the second (Supplementary  220   Table 1 ). 221

The first experiment was designed to target a viable cell density at infection of approximately 222 4 or 12 × 10 6 cells/mL with a center point of c. 8 × 10 6 cells/mL; a perfusion start time The difference in triggering of perfusion start time between the two experiments provided a 238 range of viable cell density at the time perfusion was started, with higher cell densities in the 239 second experiment than the first. The experiments were performed successively, enabling 240 observations made during the first experiment to inform design of the second. For the 241 second experiment the maximum fill volume during the last shake flask cultivation step was 242 reduced to 10% (to reduce aggregation of the cells before inoculation of the Ambr250 HT 243 Perfusion bioreactor vessels). In addition, nutrient supplementation was increased by 244 addition of 5% feed solution at the bioreactor bleed three days after inoculation (to support 245 the higher cell densities in the second experiment). 246

Analyses were performed using MODDE version 13 (Sartorius). The main analysis 251 combined the two experiments using a dummy variable denoting each experiment (EXP). To 252 combine the experiments, the perfusion start-time factor (PST) was replaced with a 253 continuous variable describing the perfusion-start viable cell density (PSVCD). Where 254 necessary, PSVCD was calculated by extrapolation or interpolation from the nearest 255 available cell count and population doubling time (in all cases, within 24 hours of perfusion 256 start). One centre-point condition reactor from experiment 2 was excluded from all analyses 257 due to microbial contamination. The response variables were normalized with a log10 258 transformation. In the main analysis, a model including the terms EXP, PSVCD, viable cell 259 density at infection (VCDI) and intensified perfusion duration (IPD) was fit by partial least 260 squares regression. Statistical significance of parameter coefficients was assessed using t 261 tests (with a null hypothesis that parameter coefficients were zero) and values of r 2 and q 2 262 were calculated using functions in MODDE as defined in the software user guide. 263

Eight sensitivity analyses were performed to evaluate the impact on the overall conclusions 264 of the following changes from the above analysis. First, the PST factor was replaced with 265 perfusion duration before infection (PDBI) instead of PSVCD. Secondly, raw response data 266 was used instead of log10-transformed data. Thirdly and fourthly, each experiment was 267 analysed individually instead of in combination. Fifthly, the experiments were pooled without 268 using the EXP dummy variable. Sixthly, three bioreactors with simplified centre-point-like 269 conditions that did not fit the full-factorial design were excluded. Seventhly, two bioreactors 270 were excluded due to initial low cell density likely resulting from error during set-up (one 271 centre-point reactor in the first experiment and one simplified centre-point-like reactor in the 272 second experiment). Finally, the model was fitted using multiple linear regression instead of 273 partial least-squares regression. 274

We designed perfusion filter dimension and flow parameters, using Repligen XCell Lab 276 technology to provide an accurate 3L scaled-down model of production at 2000L scale. A 277 0.022 m 2 filter (ATF1, Repligen) used with alternating tangential flow at 5 L/m 2 /min to 278 exchange medium at 3 L/day (0.11 L/m 2 /min) provides shear rate (1516 s -1 ) and other fluid 279 dynamic parameters similar to those of an 11 m 2 filter (ATF10, Repligen) used for perfusion 280 of a 2000 L bioreactor of circa 1500 L working volume under recommended conditions. intelligent sensor management (Mettler Toledo). The submerged addition line was welded to 285 the bioreactor connection line of an XCell ATF 1 single-use hollow-fibre filter and pump 286 device (Repligen) with a 0.22 µm pore size, 1 mm lumen and a 218 cm 2 nominal surface 287 area. Alternating tangential flow was set to 0.11 L/min (5 L/m 2 /min) using an XCell Lab 288

Controller (Repligen). The desired rate of medium exchange was achieved by controlling the 289 flow rate of the permeate (spent medium) and adding new medium, both via the BioFlo320 290 integrated pumps (after calibration). The new medium feed pump was controlled by a 291 gravimetric feedback loop programmed to maintain constant reactor weight. 292

Bioreactor growth medium was BalanCD HEK293 supplemented with 4 mM L-alanyl-L-293 glutamine, 0.01% antifoam C emulsion (Sigma-Aldrich) and 10-20% BalanCD feed (Irvine). 294

Bioreactors were stirred at 160-180 rpm (26-33 W/m 3 ) and maintained at 37°C using a 295 heating jacket. Dissolved oxygen was controlled at >55% by sparging with air and/or O2 via a 296 cascading control loop. The pH was controlled at 7.30 (dead-band, 0.1) by sparging with 297 CO2 or addition of 7.5% sodium bicarbonate. Initial T-REx-293 cell density was 0.5 to 2 × 10 6 298 viable cells/mL in a working volume of or 3 L. After infection with ChAdOx1 nCoV-19, 299 samples were taken daily for adenoviral vector quantification and biochemical analysis using 300 a Stat Profile Prime analyser (Nova Biomedical). 301

Cells were lysed 42-48 hours after infection with ChAdOx1 nCoV-19 by addition of 1/9 303 culture volume of 10% v/v polysorbate 20, 50% w/v sucrose and 20 mM MgCl2 in 500 mM 304 tris pH 8.0, 15 minutes after addition of benzonase to a final concentration of 100 U/mL 305 (Merck Millipore). Dissolved oxygen and pH were uncontrolled during lysis but stirring and 306 temperature control continued. After two hours, the lysate was clarified over 270 cm 2 307 Millistak+ HC Pro C0SP depth filters coupled with Opticap XL150 0.2 µm sterile filters at a 308 flow rate of 3.3 L/min/m 2 as previously described (4). Turbidity was measured using a TN-309 100 waterproof turbidimeter (Thermo Scientific Eutech). 310

In one experiment, the clarified lysate was concentrated by tangential flow filtration at 311 5 L/min/m 2 using a KR2i KrosFlo (Repligen) with Pellicon 2 mini cassettes (300 kDa, 0.1 m 2 , 312

BioMax polyethersulfone membrane with C-screen; Merck), as previously described (4), but 313 with the addition of a KRJr permeate control pump (Repligen) set to 0.66 L/min/m 2 . Feed 314 pressure was controlled at 0.7 bar by an automated backpressure valve on the retentate the weight of the process reservoir. After 2-fold concentration, the retentate underwent 317 diafiltration with one diavolume of ion exchange wash buffer (222mM NaCl, 1mM MgCl2 and 318 5% w/v sucrose in 50mM TrisHCl, pH 8.0, with a conductivity of 23-24 mS/cm). 319

After clarification, lysates were purified by ion-exchange chromatography. AEX was 321 preceded in one case (experiment CJ74) by limited tangential flow filtration as described 322 above, and in others by dilution of lysate 1:3 with wash buffer (as above). Before 323 chromatography, the conductivity of the lysate was adjusted to 23-24 mS/cm using 5M 324

NaCl. Fresh single-use SartobindQ capsules with 150 mL bed volume and 8 mm bed height 325 were used in a peristaltic pump-driven rig incorporating single-use ultraviolet absorbance, 326 conductivity and pressure sensors (Pendotech), as previously described (4). Capsules were 327 washed, equilibrated, loaded and eluted in accordance with the manufacturers instructions. 328

Briefly, the membrane was sanitized with 30 membrane volumes (MV) of 1M NaOH at 1 329 MV/minute, activated with 10 MV of 1M NaCl at 2 MV/minute, and equilibrated with 20 MV of 330 ion exchange wash buffer (see above) at 2 MV/minute. Samples were applied at 2.5-3.0 331 MV/minute, washed as per the equilibration step, and eluted with 5 MV of 444 mM NaCl, 332 1mM MgCl2 and 5% w/v sucrose in 50mM Tris HCl, pH 8.0, with a conductivity of 39-40 333 mS/cm, at 2 MV/minute. Eluate was collected into a reservoir containing a 'cushion' of 334 charge buffer (35mM NaCl, 10mM histidine, 1mM MgCl2, 0.1 mM EDTA, 7.5% w/v sucrose, 335 0.5% v/v ethanol, pH 6.6). 336

After ion-exchange chromatography, the eluate buffer was exchanged with 6 diavolumes of 337 formulation buffer A438 without polysorbate 80. This final tangential flow filtration step was 338 performed using Pellicon 2 mini cassettes (as above) with a feed flow rate of 5 L/min/m 2 , a 339 feed pressure of 0.7 bar, and a permeate flow rate of 0.66 L/min/m 2 (matched by the rate of 340 addition of fresh A438 via an automated auxiliary pump). Finally, polysorbate 80 341 concentration was added to a final concentration of 0.1% v/v and the product was passed 342 through 0.2 µm filters (Nalgene). 343

ChAdOx1 nCoV-19 was quantified as previously described, using quantitative PCR (qPCR) 345 and ultraviolet spectrophotometry assays for viral particles and a cell-based immunostaining 346 assay for infectious units (4). ChAdOx1 nCoV-19 in cell-culture samples was quantified harvesting. ChAdOx1 nCoV-19 in ion-exchange eluate samples and in purified product was 349 quantified by ultraviolet spectrophotometry before addition of polysorbate 80. 350

To improve qPCR accuracy, each sample was assayed in triplicate wells on triplicate plates 351 with standard curve samples (10 6 to 10 10 genome copies spaced at tenfold intervals) and two 352 internal controls. These comprised research-grade ChAdOx1 nCoV-19 purified by CsCl 353 gradient ultracentrifugation and quantified by spectrophotometry, and clinical-grade 354

ChAdOx1 nCoV-19 quantified by a GMP-qualified external qPCR assay (Advent, IRBM SpA, 355

Italy). The acceptance criteria for qPCR values were: accuracy of internal controls within 356 15%; efficiency of 90-110%, and standard curve linearity (R 2 ) of at least 0.99. 357

Residual host-cell protein (HCP) was quantified using the HEK293 HCP ELISA kit (Cygnus 358

Technologies) according to the manufacturer's instructions. Residual host-cell DNA was 359 quantified using the previously reported qPCR method, with a lower limit of quantification of 360 100 pg/mL for intact HEK293 cell DNA (4). Polyacrylamide gel electrophoresis was 361 conducted using standard molecular biology laboratory techniques. 362

Samples were diluted to 3-5 × 10 11 VP/mL in water as required and applied to freshly glow 364 discharged, carbon filmed, 300-mesh copper grids (TAAB Laboratories). Grids were 365 incubated at room temperature for 2 minutes, blotted, immediately transferred to a 20 µL 366 droplet of 2% uranyl acetate for 10 s, then blotted and air dried. Images were acquired at 367 120 keV on a Tecnai 12 transmission electron microscope (ThermoFisher) equipped with a 368

OneView camera (Gatan). 369

Models were constructed and evaluated using Biosolve software (Biopharm Services). As a 371 starting point, we used our previously described model of a 2000 L fed batch process (5) . 372

We made the following minor modifications to this base model based on subsequent 373 experience: durations of each step in the seed train were revised to reflect a 36h cell 374 population doubling time, and overall recovery in the downstream process was reduced from 375 65% to 50%. To model a 2000 L perfusion process, we examined two seed-train and 376 production bioreactor configurations. First, we considered minimal change from the fed-377 batch seed train, with seeding of the production bioreactor from a 200 L 'n-1' bioreactor, no 378 use of perfusion, and 7 days of cell expansion in a single production vessel to reach a 379 density of approximately 6 × 10 6 cells/mL before infection. Secondly we considered using a expansion (reducing the time spent by each batch in the production vessel by 72h), with the 382 single 'n-1' reactor servicing two 2000 L production bioreactors alternately. 383

At the harvest stage, the benzonase concentration was increased from 15 units/mL in the 384 fed batch process model to 100 units/mL in the perfusion model. Filter loadings in the 385 perfusion downstream process model were based upon those used in the fed-batch 386 downstream process, assuming a 4-fold increase in both product and host cell material for a 387 given volume of upstream culture. Volumetric loadings of the clarification, pre-anion-388 exchange filter (0.8/0.2 μm) anion-exchange filter, tangential-flow filter and bioburden 389 reduction filter were thus all reduced to 25% of those used in the fed-batch model. 390

Concentration in the tangential-flow filtration stage was limited to 0.33 x the bioreactor 391 volume, corresponding to an expected product concentration of 2-3 x 10 12 VP/mL. All these 392 values were in line with our experimental experience. 393

Most adenovirus production methods involve infection of all producer cells in a 'single hit' 396 with an MOI above 1 IU/cell, followed by harvest approximately two days later, after a single 397 viral lifecycle. Our previous work has used such processes throughout seed amplification. 398

After limiting dilution to isolate clonal virus, we have typically used adherent cells to perform 399 approximately 4 amplification steps in a pre-GMP laboratory. At each stage, virus is 400 recovered by freeze-thaw-mediated cell lysis and the infectious titer in the lysate is 401 measured to determine the MOI to use for the following step. A large 'safety factor' is 402 typically allowed at each stage (i.e. oversizing to allow for the possibility of poor output). 403 GMP master virus seed and working virus seed production then proceeds similarly, but in 404 stirred tank reactors and using more efficient detergent-mediated lysis. It would be 405 challenging to produce sufficient working virus seed using this approach to meet the needs 406 of a global campaign where MOI is above 1 IU/cell in the manufacturing process. This was 407 one of the factors which motivated development of the novel 'two viral lifecycle' process 408 currently used for ChAdOx1 nCoV-19. Use of an MOI considerably less than 1 IU/cell in 409 effect allows an additional cycle of viral replication to occur within the production bioreactor, 410 and substantially reduces the requirement for input working virus seed. To summarize, our minimum number of amplification steps, and hence the minimum burden of testing between 416 stages. By facilitating production of much larger quantities of working virus seed than 417 previously, this new approach also enables a high-MOI production process. 418

Because low-MOI processes have now been extensively characterized in suspension cells, 419

including the use of highly efficient detergent-mediated (rather than freeze-thaw) lysis to 420 recover virus, we sought to make the earliest possible transition to suspension cell culture. 421

To minimize delays for testing, we made the assumption that virus grown in cells from a 422 previously tested master cell bank by skilled operators is highly unlikely to be contaminated 423 with bacteria or mycoplasma. This allows immediate transfer of working virus seed to new 424 facilities with acceptable financial risk (or on the basis of rapid assays). To further streamline 425 testing between amplification steps, we reasoned that calculation of MOI on the basis of 426 genome-containing viral particles would be an accurate enough estimate of infectious titre, 427

given that particle:infectivity ratios are rarely outside the range 30 to 300. This approach 428 would enable rapid qPCR assay of the input virus, rather than a time-consuming infectivity 429 assay. Incorporation of depth filter clarification, anion exchange and 0.2 μm filtration, using 430 appropriately scaled versions of the established downstream unit operations, would provide 431 low bioburden seed virus in a controlled buffer matrix without detergent. 432

We designed a seed amplification workflow based upon these principles. We estimated that 433 a single uncontrolled-MOI amplification step in adherent cells in a 6-well plate, followed by a 434 low-MOI suspension-cell-based amplification step in a 30 mL shake flask would provide 435 sufficient pre-master seed to infect a 50L stirred-tank bioreactor. This in turn could provide 436 both ≥10 000 doses of clinical trial drug substance and adequate master virus seed to meet 437 the needs of a global production campaign ( Figure 1 , Table 1 ). 438

To test this workflow we performed a simulated low-MOI pre-master working virus seed step 439 at 30 mL scale. After infection at a qPCR-determined MOI of 6 VP/cell, we obtained an 440 output of 4.5 × 10 12 VP, or greater than 20 times more than required in our workflow to infect 441 a 50 L bioreactor for production of working virus seed. We used a 3 L culture volume in a 442 stirred-tank bioreactor as a model of both 50 L scale master virus seed production and 443 2000 L working virus seed production. This provided 1.7 × 10 11 VP/mL of culture, again 444 substantially exceeding that required by the workflow (Table 1) . antigen sequencing. Working viral seed could be provided to globally distributed large-scale 448 manufacturing sites at the same time. This in turn could permit release of fully tested vaccine 449 at large scale after a further 35 days, i.e. in a total of less than 100 days from pathogen 450 identification ( Figure 1) . 451 

The above work suggested that relatively simple modifications to our viral seed production 488 process could achieve speed compatible with the CEPI '100 day' target.(1). We next wished 489 to improve volumetric productivity, to increase the rate of vaccine output beyond the first 490 batch. 491

We initially sought to determine the effect of cell density in limiting volumetric productivity of 492

ChAdOx1 nCoV-19 in T-REx-293 cells, using a scaled-down fed-batch process in shake 493 flasks. Volumetric productivity was not improved by increasing cell density above 4 x 10 6 494 cells/mL at infection, due to declining cell-specific productivity (Figure 2 ). Maximal volumetric 495 productivity before downstream processing was approximately 4 × 10 11 VP/mL. 496 

We next sought to explore conditions under which a perfusion-based process might enhance 507 productivity while adding as little complexity as possible to the process. We used the 508 Ambr250 HT perfusion multi-parallel bioreactor system with ATF-mode medium-exchange 509 units (Figure 3a Figure 2) . 524

The regression model indicated that longer intensified perfusion duration significantly 525 improved both cell-specific productivity (p < 0.01) and volumetric productivity (p < 0.05) 526 ( Figure 3 h-i) . Lower viable cell density at infection significantly improved cell-specific 527 productivity (p < 0.001) but not volumetric productivity. The effect of perfusion start viable 528 cell density was not statistically significant, but trended towards increased productivity with 529 earlier perfusion start. Productivity metrics were also statistically significantly influenced by 530 whether the bioreactor was part of the first or second experiment (which used slightly 531 different cell culture conditions). We did not consider this to be of concern, as our aim was to 532 gather information on the influence of each factor (which was consistent between 533 experiments, as per the sensitivity analyses), rather than to predict absolute values of the 534 responses in a hypothetical future experiment. 535

Under the optimal modelled conditions, cell-specific productivity before downstream 536 processing was predicted to exceed 10 5 VP/cell and volumetric productivity to exceed 537 10 12 VP/mL. (Figure 3j ). The highest observed volumetric productivity was 1.3 × 10 12 VP/mL, 538 in two bioreactors in the first experiment which had viable cell density at infection of 6 and 11 539 × 10 6 cells/mL (Supplementary Table 1 ). This was not associated with impaired cell-specific 540 productivity, which remained at approximately 1 × 10 5 VP/cell in both these bioreactors. 541

Volumetric and cell-specific productivity were close to these maximum values in simplified 542 center-point-like bioreactors in both experiments, where perfusion was started early but was We next tested a new upstream process using ATF medium exchange in three independent 564 accurately simulated production runs in 3L single-use bioreactors. Conditions were similar to 565 those in the simplified center-point-like bioreactors in the multi-parallel experiments, with 566 early perfusion start but no intensification. Perfusion with 1 vessel volume per day starting 567 48 hours before infection, at a viable cell density of approximately 3 × 10 6 cells/mL, resulted 568 in a viable cell density at infection of 6.5-7.0 × 10 6 cells/mL across the three runs (Figure 4a ; 569 Table 2 ). Viable cell density peaked at around 1 × 10 7 cells/mL and viability then declined as 570 expected during viral replication. Volumetric productivity before downstream processing was 1.4-1.6 × 10 12 VP/mL across the 578 three simulated production runs and cell-specific productivity was 1.5-1.6 × 10 5 VP/cell 579 (Table 2) . 580 

Volumetric productivity (VP/mL of culture) 1.4 × 10 12 1.6 × 10 12 1.6 × 10 12 Viable cell density at start of perfusion (cells/mL) 2.8 × 10 6 3.6 × 10 6 3.5 × 10 6 Viable cell density at infection (cells/mL) 6.5 × 10 6 7.0 × 10 6 6.9 × 10 6 Viable cell density at peak (cells/mL) 9.6 × 10 6 1.0 × 10 7 1.0 × 10 7 Cell-specific productivity (VP/cell) based on peak viable cell density 1.5 × 10 5 1.6 × 10 5 1.6 × 10 5 Complete process Volumetric productivity (VP of DS / mL of upstream culture) 8. Table 2 for productivity data.

To assess compatibility of our new upstream perfusion-based process with the existing 597 downstream process, we purified product from the three independent upstream runs using 598 two versions of our previously published method (5) . These comprised clarification by 599 combined depth filtration and 0.2 µm filtration (Figure 5a) , purification by anion-exchange 600 chromatography (Figure 5b) , and formulation by tangential-flow filtration and 0.2 µm 601 filtration. Product recovery after each step and filter loadings were within the expected 602 ranges (Supplementary Table 2 ). Addition of an extra tangential-flow filtration step after 603 clarification in one run did not alter product recovery (Supplementary Table 2 ). 604 Quality assays indicated that particle-to-infectivity ratio and host cell protein and DNA 605 content were within the acceptable ranges for all three runs ( Table 2 ). The product contained 606 the same viral capsid proteins as product derived from the conventional process (Figure 5c ). 607

The presence of an expected minor component of empty viral capsids, consistent with 608 chromatographic purification, was confirmed by density gradient ultracentrifugation ( Figure  609 5d) and electron microscopy (Figure 5e ). Volumetric productivity after downstream 610 processing was approximately 8 × 10 11 VP of drug substance per mL of bioreactor culture, 611 with very similar values across the three runs ( This productivity implies that, despite the increased seed requirements of a high MOI 615 process, WVS from a single 2000L bioreactor run (table 1) would be sufficient to produce 616 >100m finished doses. This calculation is based upon assumptions we believe to be 617 cautious i.e. output of 5.3x10 16 VP per 2000L WVS reactor, particle : infectious unit ratio of 618 100, 33% wastage due to QC and aliquoting, and infection at 6 × 10 6 cells/mL with an MOI of 619 5 IU/cell. 620 

We next constructed a techno-economic model using Biosolve software, informed by our 641 small-scale experimental data and our previous model of a 2000 L fed-batch process (5) to 642 estimate the costs, consumables and equipment requirements for a 2000L perfusion-based 643 process. 644

We examined two scenarios for use of the seed train, production bioreactor and downstream 645 process train. The first scenario comprised a single seed train, culminating in a 200 L non-646 perfusion 'n-1' reactor, a single 2000 L production reactor, and a single downstream process 647 train. This required slow turnaround of the production vessel (c. 10 day cycle time, 648 comprising 7 days of cell expansion, 2 days of infection, 1 day of cleaning/ preparation) and 649 hence low utilization of the downstream process train. In the second scenario, a 200 L 650 perfusion-enabled 'n-1' reactor was added to the seed train (reducing the duration of cell 651 expansion in the production bioreactor) and used to serve two 2000 L production reactors. 652

This approach would provide a batch for downstream processing approximately every 4 653 days ( Figure 6 ). By more than doubling utilization of the seed train and purification train, this 654 approach could more than double output from a suite with a proportionally small increase in 655 required footprint. Modelling of the downstream process suggested it could be executed with 656 moderate modification to the equipment used for the fed-batch process, and within the 657 capacity of typical off-the-shelf equipment (Figure 6 ). The large volumes of buffer required 658 for AEX are notable: we have not attempted to reduce buffer requirements at this stage and 659 believe it is likely to be feasible to achieve substantial reduction by shortening equilibration 660 and wash steps. 661

Assuming 70% facility utilization, a single such facility is predicted to be capable of 662 production of approximately 1.2 billion doses per year, with a cost of goods below 0.20 663 EUR/dose. Under an alternative assumption of short-term maximum-capacity operation for 664 emergency response, we estimate that 8 such facilities (i.e. total installed bioreactor capacity 665 of 32 000L) could provide a total of one billion doses per month. 666 which are already well-established for drug substance production, at pre-master and master comparability of vaccine produced using different upstream processes for the initial trial 710 batch and large-scale production. Speed of the process depends critically on willingness of 711 the GMP seed production facilities to accept incoming starting material before 712 microbiological testing is completed. We believe that each step of the seed production 713 process is robust and that risks of assay failures are low but it would nonetheless seem 714 prudent, on both public health and financial grounds, to invest additional effort in mitigating 715 risks of failure. A fully standard-operating-procedure-defined and validated version of the 716 process described here, preferably including an independent parallel 'back up campaign' 717 and supported by rapid-turnaround platform analytics (notably easily-accessible nucleic-acid 718 based adventitious agent assays), would in our view provide high confidence of success. 719

Beyond first large-scale supply, the time to reach output milestones (such as the billionth 720 dose) is a function of the resources committed (e.g. m 2 of production facility) and the output 721 in doses per m 2 per day. The latter is a function of volumetric productivity and cycle time. 722

The novel perfusion-based upstream process for ChAdOx1 nCoV-19 production which we 723 have described here boosts volumetric productivity by around four fold compared with the 724 current process (reaching approximately 8 × 10 14 VP of purified drug substance per liter of 725 bioreactor culture, sufficient for >10,000 doses of DP). To our knowledge this is the first 726 demonstration that perfusion can improve productivity of a species E adenoviral vector or a 727 simian adenoviral vector. We are not aware of any other reported process achieving greater 728 productivity with such vectors. 729

Our 'design of experiments' approach on the Sartorius Ambr 250 HT perfusion system 730 identified early perfusion start and intensified perfusion after infection as factors that 731 improved volumetric productivity. We included early perfusion start but not intensified 732 perfusion after infection in the design of a new perfusion-based upstream process for testing 733 in a 3 L system. In this work we demonstrated reproducible performance of the process, 734 using a constant rate of perfusion (1 vessel volume per day) from 48 hours before infection 735 to harvest at 48 hours after infection. Our rationale for not intensifying perfusion was that 736 facilities manufacturing ChAdOx1 nCoV-19 are already capable of handling 1 vessel volume 737 per day of medium (as a requirement of the current process), but may not be capable of 738 handling intensification to 2 vessel volumes per day. The large improvement in upstream 739 productivity is compatible with the existing downstream process. We demonstrated product 740 recovery (approximately 50%) and product quality in line with expectations. 741

The work described here was facilitated by the fact that adenovirus production remains a 742 brief batch process, rather than a long continuous process (in which issues such as filter model systems. We believe this may be the first published report of such multi-parallel 745 optimization of any perfusion process ('design of experiments' in a total of 25 reactors, 746 enabled by the first published use of the Ambr250 HT perfusion system). It may also be the 747 first published report of use of the XCell Lab ATF controller and ATF1 filter system (enabling 748 accurate modelling of ATF filter dynamics in a 2000 L process at 3 L laboratory scale). 749

We used a techno-economic model to consider equipment/facility requirements and 750 campaign design to enable high output (doses per m 2 per day) from this process. We 751 estimate that a single facility housing two 2000L production bioreactors might achieve short-752 term output of around 120m doses/month. We believe numerous existing facilities (including 753 several in low-and middle-income countries) would be suitable for this. Cost per dose of 754 drug substance would be expected to be around half that of that achieved with the current 755 fed-batch process. There is clearly uncertainty in making projections based upon linear 756 scale-up of a small-scale process, but our 3L process was designed carefully as an accurate covid-19-vaccine-astrazeneca-epar-product-information_en.pdf. 

Coalition for Epidemic Preparedness Innovations launches plan to tackle risk of

Manufacturing a 820 chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs

From the first to the third generation adenoviral 823 vector: what parameters are governing the production yield?

Production of adenovirus vector for gene therapy

Influence of HEK293 metabolism 828 on the production of viral vectors and vaccine

Reassessing culture media and critical 830 metabolites that affect adenovirus production

293 cell 832 cycle synchronisation adenovirus vector production

Characterization of changes in PER.C6™ cellular 834 metabolism during growth and propagation of a replication-deficient adenovirus vector

Effect of re-feed strategies and 837 non-ammoniagenic medium on adenovirus production at high cell densities

Effect of ammonia production on intracellular 840 pH: Consequent effect on adenovirus vector production

Optimization of HEK-293S cell 842 cultures for the production of adenoviral vectors in bioreactors using on-line OUR 843 measurements

High-titer adenovirus vector production in 845 293S cell perfusion culture

Our World in Data. Coronavirus (COVID-19) vaccinations: which vaccines have been 862 administered in each country?

Kinetics of Immune Responses Elicited by Covid-19 Vaccines

Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial 873 increase following late boosting

875 Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine